Alan B. Lancz & Associates, Inc. Astrazeneca PLC Transaction History
Alan B. Lancz & Associates, Inc.
- $108 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding AZN
# of Institutions
1,361Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.05 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.71 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.4 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.37 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.23 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $200B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...